8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4 Linagliptin Intermediate Purity ≥99.0% (HPLC) Factory

Name: 8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine  CAS: 666816-98-4 Purity: ≥99.0% (HPLC) Appearance: White to Off-White Powder Intermediate for Linagliptin (CAS: 668270-12-0) for the treatment of adults with type 2 diabetes mellitus. High Quality, Commercial Production E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer Supply Linagliptin and Related Intermediates: Linagliptin CAS 668270-12-0 Linagliptin Parent Nucleus Intermediate CAS 853029-57-9 8-Bromo-3-Methylxanthine CAS 93703-24-3 8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4 2-(Chloromethyl)-4-Methylquinazoline CAS 109113-72-6 (R)-3-(Boc-Amino)piperidine CAS 309956-78-3 (R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4 1-Bromo-2-Butyne CAS 3355-28-0
Item Specifications
Appearance White to Off-White Powder
Water (K.F) ≤0.50%
Residue on Ignition ≤0.50%
Purity/Analysis Method ≥99.0% (HPLC)
Max Single Impurity ≤0.50%
Residual Solvents
Ethanol ≤5000ppm
DMF  ≤3000ppm
Test Standard Enterprise Standard
Usage Intermediate for Linagliptin (CAS: 668270-12-0)

Description:

Specifications:

Package & Storage:

Chemical Name 8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine
Synonyms 8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1H-purine-2,6-dione; Linagliptin Intermediate C
CAS Number 666816-98-4
CAT Number RF-PI497
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C10H9BrN4O2 
Molecular Weight 297.11
Melting Point 285℃
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine (CAS: 666816-98-4) is an intermediate for Linagliptin (CAS: 668270-12-0). Linagliptin is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once daily use for the treatment of adults with type 2 diabetes mellitus. Linagliptin was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours